Cypherpunk Technologies Inc. (CYPH)
NASDAQ:CYPH
Want to see CYPH full AI Analyst Report?
CYPH Stock Chart & Stats
$0.74
-$0.02(-3.02%)
―
--
Day’s Range― - ―
52-Week Range$0.23 - $3.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)6.62M
Market Cap
$78.70M
Enterprise Value$36.52M
Total Cash (Recent Filing)$6.69M
Total Debt (Recent Filing)$38.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding106,464,485
10 Day Avg. Volume10,678,913
30 Day Avg. Volume6,621,191
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.75
Enterprise Value/Market Cap0.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported debt (~$0.04M) materially reduces near-term solvency and covenant risk. This balance sheet conservatism provides durable financial flexibility to pursue restructurings, R&D, or equity financings over the next several months without immediate debt pressure.
Addressable Market TailwindA strategic focus on privacy and security aligns with long-term regulatory and consumer demand for data protection. Structural tailwinds across industries support recurring product need and potential diversified customer opportunities over a 2–6 month horizon and beyond.
Orderly Board RefreshMultiple board retirements were disclosed as planned and amicable, suggesting a controlled governance refresh. Orderly transitions lower the risk of abrupt strategic disruption and can enable clearer succession planning and renewed oversight in upcoming quarters.
Bears Say
Severe Cash BurnHighly negative operating and free cash flow indicates the business is not self-funding and will likely require external capital. Persistent cash burn amplifies financing and dilution risk, constraining strategic optionality and increasing probability of near-term fundraising actions.
Weak Revenue TractionMinimal revenue versus outsized losses shows the cost base far exceeds market monetization to date. Without meaningful, sustainable revenue growth, margins cannot normalize and the business model remains unproven, creating structural risk to recovery over several months.
Equity ErosionA sharp decline in book equity reflects accumulated losses and potential dilutive financings. Erosion of shareholder equity weakens the capital base, reduces ability to absorb future losses, and heightens the likelihood of financing that could dilute existing owners.
Cypherpunk Technologies News
CYPH FAQ
What was Cypherpunk Technologies Inc.’s price range in the past 12 months?
Cypherpunk Technologies Inc. lowest stock price was $0.23 and its highest was $3.70 in the past 12 months.
What is Cypherpunk Technologies Inc.’s market cap?
Cypherpunk Technologies Inc.’s market cap is $78.70M.
When is Cypherpunk Technologies Inc.’s upcoming earnings report date?
Cypherpunk Technologies Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were Cypherpunk Technologies Inc.’s earnings last quarter?
Cypherpunk Technologies Inc. released its earnings results on May 14, 2026. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.46.
Is Cypherpunk Technologies Inc. overvalued?
According to Wall Street analysts Cypherpunk Technologies Inc.’s price is currently Undervalued.
Does Cypherpunk Technologies Inc. pay dividends?
Cypherpunk Technologies Inc. does not currently pay dividends.
What is Cypherpunk Technologies Inc.’s EPS estimate?
Cypherpunk Technologies Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cypherpunk Technologies Inc. have?
Cypherpunk Technologies Inc. has 106,464,485 shares outstanding.
What happened to Cypherpunk Technologies Inc.’s price movement after its last earnings report?
Cypherpunk Technologies Inc. reported an EPS of -$0.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Cypherpunk Technologies Inc.?
Currently, no hedge funds are holding shares in CYPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cypherpunk Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 404.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.48%
12-Months-Change
Fundamentals
Return on Equity
-46.86%
Trailing 12-Months
Asset Growth
150.52%
Trailing 12-Months
Company Description
Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Ownership Overview
2.33% Insiders
2.12% Mutual Funds
0.28% Other Institutional Investors
93.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---